Talent Pool

Contributed by:

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

Pharma POOL Matthew E. Czajkowski aaiPharma Appoints Executive VP, Chief Financial Officer Matthew E. Czajkowski has been appointed executive VP and chief financial officer of aaiPharma, Wilmington, N.C., a science-based pharmaceutical company focused on pain management. Mr. Czajkowski, 55, previously worked at Pozen as senior VP, finance and administration, and chief financial officer. Mr. Czajkowski received a bachelor’s degree from Harvard University and a MBA from Harvard Business School. John Kelley The Medicines Company Appoints President and Chief Operating Officer John Kelley has joined The Medicines Company in the newly created position of president and chief operating officer. The Medicines Company, Parsippany, N.J., develops products that improve acute hospital care. Mr. Kelley’s primary responsibility is to oversee the company’s commercial operating business units as well as manufacturing. He brings 30 years of pharmaceutical industry experience to this position. Most recently, he was a senior VP at Aventis, where he was accountable for worldwide brand management of all major franchise areas. Dr. Ted Lithgow Karl D. Salnoske Schering-Plough Appoints VPs Schering-Plough, Kenilworth, N.J., has named Ted Lithgow, Ph.D., group VP of commercial development. Dr. Lithgow has been promoted from VP of commercial development for Schering-Plough’s global pharmaceutical business. Schering-Plough is a global science-based healthcare company with leading prescription, consumer, and animal-health products. In this new role, Dr. Lithgow coordinates the interaction between the global pharmaceutical business, Schering-Plough Research Institute (SPRI), and the global supply-chain organizations to develop and commercialize the company’s product pipeline. He also is a member of the global pharmaceutical business management team and is responsible for achieving effective collaboration across the organization and ensuring that the company makes the best use of resources in creating value for patients, healthcare providers, and other stakeholders. Additionally, Dr. Lithgow assumes responsibility for providing product profile direction to senior management at SPRI and serves as the key liaison with global licensing on the valuation and assessment of in-licensing projects. Before joining Schering-Plough in 2003, Dr. Lithgow was VP of commercial development operations and emerging technologies at Pharmacia. He holds a B.A. in biology and psychology from Muhlenberg College, a M.Phil. in biopsychology from The City University of New York, and a Ph.D. in psychopharmacology from The City University of New York and Albert Einstein College of Medicine. Karl D. Salnoske has joined Schering-Plough as VP and chief information officer. Mr. Salnoske directs the planning, acquisition, development, and operation of computer, telecommunication, and information systems for Schering-Plough’s offices worldwide. He also is responsible for establishing the technical infrastructure and setting strategic guidelines for use of information systems technology throughout the company. Previously, Mr. Salnoske was president and CEO of Adaptive Trade, which provided decision-optimization tools to the energy and process manufacturing industries. He holds a B.S. in electrical engineering from Virginia Polytechnic Institute, where he sits on the advisory board for the department of electrical and computer engineering. Dr. William Stagner Pozen Names Senior VP of Program Management and Development Planning Pozen, Chapel Hill, N.C., has appointed William Stagner, R.Ph., Ph.D., as senior VP of program management and development planning. Dr. Stagner is responsible for managing project development teams and programs at Pozen, a pharmaceutical company committed to developing therapeutic advancements for diseases with unmet medical needs. Dr. Stagner has 25 years of pharmaceutical development experience. Most recently, he served as senior VP and general manager at Cardinal Health Pharmaceutical Development. He received his B.S., M.S., and Ph.D. degrees from the University of Iowa, College of Pharmacy. Biotech POOL Dr. John E. Bishop Michael A. Lawless Momenta Appoints Manufacturing Management and Investor Relations Executives Momenta Pharmaceuticals has appointed John E. Bishop, Ph.D., as VP of pharmaceutical sciences and manufacturing. Momenta, Cambridge, Mass., is a biotechnology company specializing in the sequencing and engineering of complex sugars for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. Dr. Bishop previously worked for Millennium Pharmaceuticals and earned his Ph.D. in organic chemistry at the University of California-Berkeley and his MBA from Northeastern University. Momenta also has named Michael A. Lawless senior director of investor relations. Previously, Mr. Lawless was senior director of finance and investor relations for CTI Molecular Imaging. Mr. Lawless holds a MBA from the Tuck School of Business Administration at Dartmouth College. Dario Eklund Organogenesis Names VP of Biosurgery and Aesthetic Medicine Dario Eklund has joined Organogenesis as VP of biosurgery and aesthetic medicine. Based in Canton, Mass., Organogenesis designs, develops, manufactures, and commercializes medical products containing living cells or natural connective tissue. Mr. Eklund is responsible for expanding the company’s biosurgery and aesthetic medicine business units. Before joining Organogenesis, Mr. Eklund worked for Aventis as country manager for Switzerland. He holds a B.Sc. in economics and a M.Sc. in business administration from the Swedish School of Economics and Business Administration. Dr. Matthias Kurth Daniel Lee Ceregene Expands Clinical Team Ceregene, a biotechnology company focused on the development of gene therapies for neurodegenerative disorders, has appointed Matthias Kurth, M.D., Ph.D., as VP of medical affairs. Dr. Kurth is supporting the company’s efforts to advance its clinical programs for Alzheimer’s disease, Parkinson’s disease, and ALS. Previously, he was involved with neurology clinical trials at Allergan. Dr. Kurth earned his M.D. and Ph.D. at Baylor College of Medicine. He trained in neurology at Stanford University and at the Parkinson’s Institute. Additionally, Ceregene has appointed Daniel Lee, M.S., as director of clinical operations. Mr. Lee joins the San Diego-based firm after 11 years with Amgen, where he was senior clinical research manager, coordinating Parkinson’s disease and ALS clinical programs. Jeff Morhet InNexus Appoints VP, Operations InNexus Biotechnology has named Jeff Morhet as VP, operations. Mr. Morhet is responsible for leading product development and coordinating planning for clinical trials at the Vancouver, Canada-based biotech company, which develops therapeutic monoclonal antibodies. Previously, he was VP and general manager for Zila, responsible for multiple clinical development, manufacturing, and FDA regulatory programs. Dr. Kerry Reinertsen Vertex Pharmaceuticals Names VP, Corporate and Business Development Vertex Pharmaceuticals has named Kerry Reinertsen, Ph.D., to the position of VP of corporate and business development. Vertex, Cambridge, Mass., focuses on the discovery and development of small-molecule drugs for serious diseases. Dr. Reinertsen is responsible for leading a variety of corporate and business development initiatives, including assessing and executing partnership opportunities. Previously, Dr. Reinertsen was senior director of product business development at Millennium Pharmaceuticals. She holds a Ph.D. in cellular and molecular biology from Harvard University and a B.A. in economics and biochemistry/molecular biology from Brown University. Biopharmaceutical POOL Dr. Pamela Joy Barton Nabi Biopharmaceuticals Names VP, Business Development Nabi Biopharmaceuticals has appointed Pamela Joy Barton, Ph.D., to the position of VP of business development. Based in Boca Raton, Fla., Nabi Biopharmaceuticals develops products that address infectious, autoimmune, and addictive diseases. Dr. Barton’s focus areas include product licensing and acquisition, technology licensing and acquisition, global expansion alliances, and merger and acquisition opportunities. Dr. Barton joins the company from Sosei, where she was VP of business development. She received a Ph.D. in pharmacology from the University of Birmingham in the United Kingdom. Paula Craft Callisto Pharmaceuticals Creates VP, Regulatory Affairs, Position Callisto Pharmaceuticals has named Paula Craft as VP of regulatory affairs. Callisto is a New York-based biopharmaceutical company focused on developing drugs to treat cancer and osteolytic bone disease. Ms. Craft is responsible for managing the regulatory affairs and product direction for the company’s two drugs beginning clinical trials this year: Annamycin for relapsed leukemia and Atiprimod for relapsed multiple myeloma. Before joining Callisto, Ms. Craft was president of regulatory compliance, quality systems, and strategic planning for Biopharmaceutical Consulting. Dr. Rebecca Dabora Altus Pharmaceuticals Names New VP, Technical Operations and Manufacturing Rebecca Dabora, Ph.D., has joined Altus Pharmaceuticals as VP of technical operations and manufacturing. The company, located in Cambridge, Mass., develops novel protein therapies to treat chronic gastrointestinal and metabolic diseases. Dr. Dabora leads the technical operations and manufacturing activities for all of Altus’ products. Previously, Dr. Dabora worked as a consultant to various biotechnology companies. She holds a Ph.D. in biochemical engineering from the Massachusetts Institute of Technology and a B.A. in biochemistry from Bowdoin College. Martin J. Duvall MGI Pharma Adds Senior VP, Commercial Operations Martin J. Duvall has joined MGI Pharma as senior VP of commercial operations. MGI Pharma is an oncology-focused biopharmaceutical company based in Minneapolis. Mr. Duvall most recently served as VP, team leader, Taxotere and new cytotoxics, global medical and marketing, at Aventis Pharmaceuticals. He received a bachelor’s degree in chemistry from Muhlenberg College, a master’s degree in chemistry from Johns Hopkins University, and a MBA from the University of Kansas. Steven Kelly Innovive Pharmaceuticals Names President and CEO Steven Kelly has been appointed president and CEO of Innovive Pharmaceuticals, a New York-based biopharmaceutical company that specializes in oncology and hematology therapeutics. Mr. Kelly has more than 15 years of commercial experience in biotech and pharmaceutical companies. Before joining Innovive Pharmaceuticals, he headed the oncology marketing group for Sanofi-Synthelabo’s U.S. division. He holds a MBA from Cornell University and a B.S. in biology and chemistry from the University of Oregon. Dr. Michael J. Manyak Cytogen Appoints VP, Medical Affairs Cytogen, Princeton, N.J., has named Michael J. Manyak, M.D., as VP of medical affairs. Dr. Manyak is the primary liaison to the medical community and is responsible for the company’s clinical science and medical affairs functions. Before joining Cytogen, a product-driven biopharmaceutical company, Dr. Manyak was the chairman of the urology department and a professor of urology, microbiology, and tropical medicine at The George Washington University Medical Center. He is also a founder of Metastatin Pharmaceuticals. Evan Myrianthopoulos Michael T. Sember DOR BioPharma Appoints Top Executives DOR BioPharma has named Evan Myrianthopoulos to the position of chief financial officer. Mr. Myrianthopoulos has been a director of the Miami-based biopharmaceutical company for two years and most recently served as the president and acting CEO. Michael T. Sember has taken over as the company’s permanent president and CEO. He has more than 30 years of pharmaceutical and biotech experience. Most recently, he served as managing director of EGB Advisors, a consulting firm and biotech incubator. Mr. Sember has served on the boards of eight biotech companies and on the advisory boards of two venture capital firms. Michael J. Nestor NanoBio Names New CEO NanoBio, Ann Arbor, Mich., has appointed Michael J. Nestor as CEO. NanoBio focuses on developing and marketing antimicrobial therapeutics based on its proprietary nanoemulsion technology. Mr. Nestor previously served as president of Alpharma Branded Products, a division of Alpharma. He holds a MBA from Pepperdine University and a bachelor’s degree from Middle Tennessee State University. Dr. Nita U. Patel New VP of Regulatory Affairs Joins GenVec Nita U. Patel, Ph.D., has been appointed to the newly created post of VP of regulatory affairs at GenVec, Gaithersburg, Md., a biopharmaceutical company that develops infectious disease vaccines and treatments for cancer, heart disease, and vision loss. Previously, Dr. Patel was senior director, regulatory affairs, global vaccines, at Baxter Healthcare. Dr. Patel received a Ph.D. in yeast genetics/molecular biology from University College in London and a B.S. with honors in biochemistry from Queen Elizabeth College in London. Specialty POOL Charles J. Casamento President and CEO of Osteologix Named Osteologix has appointed Charles J. Casamento as CEO, president, and director. With headquarters in San Francisco and Copenhagen, Osteologix is focused on the preclinical and clinical development of pharmaceutical products for the treatment of bone diseases, such as osteoporosis. Mr. Casamento has a strong track record in the pharmaceutical and biotech industries. He is a registered pharmacist and holds a MBA and a B.Sc. in pharmacy. Previously, he served as CEO for Interneuron and RiboGene, which later became Questcor Pharmaceuticals. Dr. Henry Kwan NovaDel Pharma Appoints Pharmaceutical Sciences Head Henry Kwan, Ph.D., has joined NovaDel Pharma as head of pharmaceutical sciences. NovaDel Pharma is a specialty pharmaceutical company based in Flemington, N.J. Previously, Dr. Kwan was VP of R&D and regulatory affairs for Eurand. He holds a Ph.D. in pharmaceutical chemistry from the University of Michigan and a B.S. cum laude in chemistry from Marquette University. He is a member of the American Association of Pharmaceutical Scientists. William H. Washecka Prestwick Pharmaceuticals Hires Chief Financial Officer William H. Washecka has joined Prestwick Pharmaceuticals, a specialty pharmaceutical company focused on treatments for central nervous system disorders, as chief financial officer. Mr. Washecka oversees the company’s finance team in the management of U.S. and Canadian operations. He also is preparing the Washington, D.C.-based company for its initial public offering. Mr. Washecka has joined Prestwick from Usinterworking, where he was chief financial officer. He is the cofounder of the Mid-Atlantic Venture Capital Conference. Device/Diagnostic POOL Dr. David Bolick Grant Life Sciences Appoints Chief Medical Director David Bolick, M.D., F.C.A.P, M.I.A.C, has joined Grant Life Sciences, Salt Lake City, as chief medical director. Grant Life Sciences develops products to improve the efficiency of diagnosing cervical cancer. Dr. Bolick is responsible for managing the company’s clinical programs and regulatory affairs. He has extensive experience developing and implementing new technologies in cervical cancer screening. Most recently, Dr. Bolick was the founder, medical director, and senior pathologist at Reference Pathology Services. He earned his M.D. at Duke University, has a fellowship in surgical pathology at Stanford University, and earned a B.S. in medical technology and microbiology from Brigham Young University. John Brannigan Wade Fox Jo Proffitt Gregg Theaker Mike Waller Tissue Science Laboratories Appoints Senior Managers Tissue Science Laboratories, a medical-devices company specializing in human tissue replacement and repair, has made key promotions and appointments. John Brannigan has been promoted to international sales and marketing director. In this role he is responsible for all of the company’s sales and marketing operations worldwide, with particular concentration on the United States. Mr. Brannigan has been with the company since 2001 and expanded the company’s distributor network throughout Europe. Tissue Science Laboratories, which has headquarters in Hampshire, England, and Covington, Ga., also has named Wade Fox marketing director, North America. Jo Proffitt has been named head of new product development, responsible for day-to-day management of the NPD team. Gregg Theaker has been promoted to sales director, North America. Mike Waller has been named executive VP of corporate development. His responsibilities include managing relationships with current strategic partners and finding new distribution partners in target market sectors. Since joining Tissue Science Laboratories in 2001, Mr. Waller has been focused on building the overall business in North America. John Kilcoyne Micrus Appoints President and CEO John Kilcoyne has joined Micrus as president, CEO, and a member of the board of directors. Micrus, located in Sunnyvale, Calif., and Yverdon, Switzerland, develops medical devices and delivery systems for neuroendovascular applications. Mr. Kilcoyne is responsible for developing the corporation’s infrastructure and product pipeline. He brings more than 20 years of operating experience to the role. Previously, he was the CEO of Solace Therapeutics. Mr. Kilcoyne holds a B.S. from Cornell University. Gary M. Saxton BioSphere Medical Appoints VP, Marketing and Sales BioSphere Medical has hired Gary M. Saxton to the position of VP of marketing and sales. Mr. Saxton is responsible for expanding the Rockland, Mass.-based company’s core embolotherapy business. Previously, Mr. Saxton was a strategy consultant in the medical-device industry. He holds a B.S. from the United States Military Academy and a MBA from Harvard University. Genomics POOL Anthony E. Altig Diversa Names Chief Financial Officer Diversa has appointed Anthony E. Altig to the position of senior VP of finance and chief financial officer. San Diego-based Diversa applies proprietary genomic technologies for the rapid discovery and optimization of novel protein-based products. Mr. Altig, 48, is responsible for the overall management of the company’s financial activities, including financial reporting, budgeting, investor relations, and treasury functions. Before joining Diversa, Mr. Altig served as the chief financial officer of Maxim Pharmaceuticals. Mr. Altig is a certified public accountant and a graduate of the University of Hawaii. Dr. Colin Dykes R.H. Joseph Shaw OpGen Appoints Two New Executive Leaders OpGen, which specializes in single molecule DNA analysis, has appointed Dr. Colin Dykes, to the position of executive VP of corporate development. In addition, Dr. Dykes maintains his responsibilities as OpGen’s chief scientific officer. OpGen, Madison, Wisc., also has appointed R.H. Joseph Shaw as CEO and a member of the company’s board of directors. His primary responsibility is to continue creating a performance-driven business that capitalizes on OpGen’s unique whole genome analysis technology Optical Mapping. Before joining OpGen, Mr. Shaw served as president of Bank On A Cure, a global study project of the International Myeloma Foundation. Tim Germann U.S. Genomics Expands Commercialization Efforts with Marketing and Sales VP Tim Germann has joined U.S. Genomics’ management team in the newly created role of VP of marketing and sales. U.S. Genomics, Woburn, Mass., is a marketer and developer of technologies that allow genetics, functional genomics, and diagnostics to be performed at the single molecule level. Mr. Germann is spearheading the creation of a dedicated salesforce for U.S. Genomics’ recently launched Trilogy platform Single Molecule Analyzer. He joins U.S. Genomics from Affymetrix, where he served as the northeast sales manager. Mr. Germann earned his B.S. degree in business management from Brigham Young University. Dr. Dennis Gilbert Applied Biosystems Selects Chief Scientific Officer and VP, Research Dennis Gilbert, Ph.D., has been named chief scientific officer and VP of research for Applied Biosystems, an Applera business based in Foster City, Calif. Additionally, Dr. Gilbert has become a VP of Applera. In this new role, he leads Applied Biosystems’ scientific and technical programs and is responsible for coordinating cross-divisional research and development efforts and leading the group’s first external scientific advisory board, as well as an internal technology board. Dr. Gilbert, 46, has more than 10 years of senior management experience at Applera. Most recently, he served as VP of Applied Biosystems Advanced Research and Technology organization. Dr. Gilbert holds a B.S. in biochemistry and cell biology from the University of California, San Diego, and a Ph.D. in genetics from Johns Hopkins University. Emerging POOL David J. Gury New Chairman Elected to Lead Oragenics Oragenics has elected David J. Gury as chairman of the company’s board of directors. Oragenics is an emerging biotechnology company based in Alachua, Fla. Mr. Gury, the retired former chairman and CEO of Nabi Biopharmaceuticals, has been a member of the Oragenics board since fall 2003. Mr. Gury also is chairman of the Florida Research Consortium and a past chairman of BioFlorida. Mr. Gury replaces Oragenics’ founder and chief scientific officer Jeffrey Hillman, D.M.D., Ph.D. Dr. Hillman stepped down as chairman to devote his full attention to Oragenics’ science and product development efforts. Dr. Elliot F. Hahn SoLapharm Appoints President SoLapharm, an emerging pharmaceutical company based in Plantation, Fla., has named Elliot F. Hahn, Ph.D., to the position of president. Dr. Hahn also is a director of the company. Before joining SoLapharm, Dr. Hahn cofounded Andrx, a generic and specialty pharmaceutical company. He remains a consultant, director, and chairman emeritus of Andrx. Dr. Hahn has authored more than 60 peer-reviewed scientific publications and has been named as an inventor on several patents. He also serves as a director of Able Laboratories and NationsHealth. Dr. Steven D. Reich Attenuon Names Chief Medical Officer, Senior VP Attenuon, has appointed Steven D. Reich, M.D., to the post of chief medical officer and senior VP. The San Diego-based pharmaceutical company is developing a new generation of cancer therapies. With more than 25 years of oncology drug development experience, Dr. Reich is responsible for planning and managing clinical development for Attenuon’s drug candidates. He previously was senior director of oncology clinical development at Pfizer. Dr. Reich earned an A.B. from Princeton University and a M.D. from New Jersey College of Medicine and Dentistry. He is board-certified in internal medicine with a subspecialty in medical oncology. He also is a member of the American Society of Clinical Oncology and the American Association for Cancer Research. Association POOL Dr. Ronald Meeusen Former Dow AgroSciences Executive Joins BioCrossroads Staff Ronald Meeusen, Ph.D., has joined BioCrossroads as chief scientific officer and special projects director. Previously, Dr. Meeusen was working with BioCrossroads as a loaned executive from Dow AgroSciences. BioCrossroads, the Indiana life-sciences initiative, is based in Indianapolis. Dr. Meeusen originally was brought on board to lead a statewide analysis of Indiana’s agriculture economy and to develop strategies to increase agriculture jobs. In this new role, he is continuing this effort and taking on additional projects. Dr. Meeusen had been with Dow AgroSciences since 1998, where he was the VP, research and development, plant genetics, and biotechnology. He received his Ph.D. in plant cell physiology from U.C. Berkeley. Patrick Vazquez Alpharma Director Named President of DCAT Association The Drug Chemical and Associated Technologies (DCAT) Association has appointed Patrick Vazquez as its president. DCAT, Robbinsville, N.J., is the business development association for companies that manufacture, distribute, or provide services to the pharmaceutical, chemical, nutritional, and related industries. Mr. Vazquez is director of U.S. sales for Alpharma’s active pharmaceutical business. He has been a member of DCAT for more than 20 years, serving in roles of increasing responsibility. Agency POOL Jennifer Alampi Jane Ames Matt Leung Vanessa Levin Torre Lazur McCann Consumer Group Names Executives Torre Lazur McCann, Parsippany, N.J., has appointed Jennifer Alampi as one of the members to lead the creative team of its new Consumer Communications Group. Jane Ames has been named president of the new agency. In this position, Ms. Ames is responsible for helping the global healthcare agency fully integrate its clients’ consumer, professional, and managed-care activities. Ms. Ames previously was with Saatchi & Saatchi Healthcare, where she served as executive VP in charge of Prilosec, Nexium, and Entocort. She earned a bachelor’s degree from Wellesley College. Matt Leung has been named VP, management supervisor, and Vanessa Levin also was named to the creative team. Dan Bobear Maggie Dearden David Paprocki Palio Communications Appoints New Staff Palio Communications has named Dan Bobear as senior VP/account director, Maggie Dearden as account coordinator, and David Paprocki as senior art director. Palio, a subsidiary of inChord Communications, is an advertising and communications firm located in Saratoga Springs, N.Y. Mr. Bobear brings 13 years of pharmaceutical and biotech marketing experience to Palio Communications. Most recently, he served as group director/marketing professional at CHS. He holds a MBA from Canisius College and a bachelor’s degree from Le Moyne College. Ms. Dearden comes to Palio from State Farm Insurance Companies, where she was a claims representative. She holds a bachelor’s degree from the University of Richmond. Before joining Palio, Mr. Paprocki was a freelance art director working with a number of agencies, including Arnold, TBWA, Brighthouse, and Ignited Minds. He earned a bachelor’s degree from Florida State University. Camille DeSantis Edelman Appoints Executive VP, Creative Director Edelman, New York, has named Camille DeSantis, MT (ASCP), to the position of executive VP, creative director. Edelman is a health-focused public relations firm with offices worldwide. Ms. DeSantis’ primary focus is on opportunities and programs within Edelman’s Rx Health and BioScience business units. Previously, she was senior VP, group creative director, at Corbett Accel Healthcare Group. She is a member of the American Medical Writers Association and the Healthcare Businesswomen’s Association. Elaine Eisen Corbett Accel Healthcare Group Names President of Chicago Advertising Corbett Accel Healthcare Group, a medical communications company with offices in Chicago, New York, and London, has promoted Elaine Eisen to president of its Chicago operations. Ms. Eisen is responsible for managing the operations of the Chicago office as well as strategic oversight for several of the agency’s key clients, including Bristol-Myers Squibb and Otsuka America Pharmaceuticals. Previously, Ms. Eisen served as executive VP and director of client services at Corbett Accel Chicago, part of Omnicom Group. She holds bachelor’s and master’s degrees in business administration from Northwestern University. Tina Fascetti Stonefly Communications Group Names Senior VP, Worldwide Creative Director Tina Fascetti has joined Stonefly Communications Group as senior VP, worldwide creative director. With headquarters in Columbus, Ohio, Stonefly is a subsidiary of inChord Communications, a global group of communications companies that provide marketing solutions to the healthcare industry. Ms. Fascetti is responsible for establishing the agency’s creative vision and providing strategic direction on all creative work. She brings more than 16 years of experience in healthcare advertising and agency management to the company. Ms. Fascetti previously served as senior VP, group creative director, at GSW Worldwide, Stonefly’s sister agency. Dr. Lauren Gallagher Dr. Alex Loeb Kelly Reith Dr. Peter Rittenhouse Dr. Kevin Ryder Sandra Teichman Complete Healthcare Communications Bolsters Editorial Staff with Addition and Promotions Complete Healthcare Communications (CHC), Chaddsford, Pa., a strategic communications company serving the pharmaceutical and biotechnology industries, has made several key appointments. Lauren Gallagher, R.Ph., Ph.D., has been promoted from editorial manager to editorial director. In this new position, Dr. Gallagher manages the firm’s editorial department of 40 staff medical directors, medical writers, and editors. She has been with the company since 2002. Previously, Dr. Gallagher was a medical director at a medical-education company. Additionally, Alex Loeb, Ph.D.; Kelly Reith, M.S.; Peter Rittenhouse, Ph.D.; and Kevin Ryder, Ph.D., have all been promoted to senior medical directors. Sandra Teichman has been named staffing development manager. In this position, Ms. Teichman helps CHC broaden its editorial recruitment efforts and hiring capabilities. Previously, she was a senior executive recruiter with an international recruitment agency. Paul Hendley A.B. Isacson Associates Names Life-Sciences Director A.B. Isacson Associates (ABI) has promoted Paul Hendley as industry director, life sciences, to develop ABI’s global client base in the pharmaceutical, biotechnology, medical-device and diagnostics, laboratory, and related health-science sectors. New York-based ABI is a business-to-business marketing public relations agency serving the industrial and high technology sectors. Mr. Hendley is responsible for monitoring industry trends and developing comprehensive client strategies in the life-sciences markets. Previously, he was instrumental in driving domestic and international programs for the company’s clients in the biopharmaceutical, medical, chemical, plastics, and packaging markets. Mr. Hendley holds a bachelor’s degree from Columbia College and a master’s degree from Indiana University. Steve Spittel Interlink Healthcare Communications Names VP, Management Supervisor Steve Spittel has joined Interlink Healthcare Communications, Lawrenceville, N.J., as VP, management supervisor. Mr. Spittel brings more than 30 years of experience in the pharmaceutical industry and experience launching nearly 20 new products to Interlink. Most recently, he served as executive VP, director of marketing, at Nelson Communications. He earned a bachelor’s degree at Manhattan College and a MBA in marketing at New York University. Consulting POOL Larry Levin Jim Perry Dr. Joe Romero Market Strategies Builds Senior Management Team Market Strategies has appointed Larry Levin, Jim Perry, and Joe Romero, Ph.D., to key management roles within its global life-sciences division. With headquarters in Livonia, Mich., Market Strategies is a full-service consulting company providing market research and analysis. Mr. Levin, Mr. Perry, and Dr. Romero are located at the company’s office in New Providence, N.J. Mr. Levin has been named senior VP. He is responsible for leading the development and management of multiclient studies within the healthcare sector. Before joining Market Strategies, he served as executive VP of TNS Healthcare’s global strategic products group. Mr. Perry has been appointed VP. He manages business development and client-service efforts for the greater New York-New Jersey area. Mr. Perry comes to Market Strategies from NOP World Health, where he was senior VP, global key account manager. Dr. Romero also was appointed VP. Previously, Dr. Romero was senior VP at NOP World Health. Dr. Romero holds a Ph.D. in sociology from Temple University. CRO POOL Dr. Pradip Banerjee Essential Group Appoints New Chairman The board of directors of Essential Group has appointed Pradip Banerjee, Pharm.D., as its chairman. Dr. Banerjee was elected to the board as a nonexecutive director in August 2004. Essential Group, Gurnee, Ill., is the operating company for Essential CRO, a full-service CRO, Essential Patient Recruitment, and AmericasDoctor, a site management network. Dr. Banerjee, 52, is the CEO of The Science Center. Dr. Banerjee earned a doctorate in pharmacy at the University of Wisconsin-Madison and a MBA at the Wharton School of the University of Pennsylvania. Dr. Nancy Gillet Glenn Kerkhof Paul A. Oskar III Christopher Perkin Charles River Laboratories Appoints Key Managers Following Merger Charles River Laboratories International, Wilmington, Mass., a global provider of solutions that advance the drug discovery and development process, has made several key appointments following its merger with Inveresk Research Group. Nancy Gillet, D.V.M., Ph.D., has been promoted to senior VP and president of global preclinical services. She succeeds Michael Ankcorn, who has retired. Dr. Gillett previously served Charles River as corporate VP and president of U.S. preclinical services. She is an ACVP board-certified pathologist, with D.V.M. and Ph.D. degrees. Glenn Kerkhof has been named interim president of global clinical services. He succeeds Alastair McEwan, who has left the company. Mr. Kerkhof also serves as VP operations, clinical Europe and Asia-Pacific, and has been with Inveresk for 11 years. He is now overseeing Charles River’s global clinical business until a successor is announced. Paul A. Oskar III has assumed the role of general manager and president of U.S. preclinical services. Mr. Oskar has been with Charles River for 22 years. Most recently, he served as general manager, DDS Worcester division. Christopher Perkin, has been named general manager and president of Canadian preclinical services. He spent 16 years with Inveresk and most recently served as chief operating officer of CTBR. Jennifer Henry-Smith Pacific Biometrics Appoints VP for Business Development Seattle-based Pacific Biometrics has named Jennifer Henry-Smith division VP for business development. Pacific Biometrics provides specialized central laboratory services to support pharmaceutical and diagnostic manufacturers conducting human clinical-trial research. Previously, Ms. Henry-Smith was director of business development at ACM Medical Laboratory. In this new role, Ms. Henry-Smith manages all East coast pharmaceutical accounts and builds the company’s overall business development strategy. She is based in LeRoy, N.Y. Ms. Henry-Smith holds a master’s degree in business administration. Media POOL Mark Altier Jeffrey R. Davis Alan Imhoff Janice Theobald Elsevier Announces Promotions at International Medical News Group Mark Altier has been promoted to sales manager, primary care, at International Medical News Group (IMNG), Moorestown, N.J., an Elsevier company. Elsevier is a publisher of scientific, technical, and medical information products and services. In this new role, Mr. Altier is responsible for advertising sales for Family Practice News, Internal Medicine News, and Cardiology News. He previously served as national account manager for Family Practice News, Internal Medicine News, and Cardiology News. Jeffrey R. Davis has been promoted to sales director at IMNG after serving as sales manager, primary care, for IMNG’s primary-care publications, Family Practice News and Internal Medicine News, as well as Cardiology News. In this new position, Mr. Davis is responsible for sales management for all nine of the IMNG specialty and primary-care publications. Elsevier has named Alan Imhoff president of International Medical News Group. Previously, Mr. Imhoff served as IMNG’s publisher/general manager. Before joining IMNG in 2001, Mr. Imhoff held publisher positions at SCP Communications and Time/Warner. Janice Theobald has been promoted to senior director of marketing and research. Ms. Theobald previously was the director of market research. Calvin Butts HMP Communications Names National Accounts Manager HMP Communications has appointed Calvin Butts as national accounts manager for Clinical Geriatrics, the official journal of the American Geriatrics Society. HMP Communications, Princeton, N.J., is a medical media company specializing in the care of the senior patient population. Mr. Butts is responsible for developing strategies to effectively tap into the senior-care market. Previously, Mr. Butts served as a professional sales representative at Eli Lilly. Jane Cammarata Slack Appoints Director of Medical Education Projects Slack, Thorofare, N.J., has appointed Jane Cammarata as director of medical education projects, pharmaceutical division. Ms. Cammarata joined Slack in May 2002 as national sales manager. In this new position, she is responsible for projects for several Slack publications, including Hem/Onc Today, Infectious Disease News, Infectious Diseases in Children, Psychiatric Annals, Pediatric Annals, Endocrine Today, and Today in Cardiology. Chris d’Eon RealAge Creates Marketing VP Position Chris d’Eon has been named to the newly created position of VP of marketing for San Diego-based RealAge, a consumer health media company and provider of personalized information and health management tools. Most recently, as founder of Deon Direct, Mr. d’Eon built strategic marketing plans for national e-commerce and media firms. Mr. d’Eon is immediate past president of the San Diego chapter of the Direct Marketing Association. Phil Molinaro Quadrant HealthCom Appoints Group Publisher Phil Molinaro has joined Quadrant HealthCom as group publisher. Quadrant HealthCom, Chatham, N.J., develops specialized communications and publishes seven medical journals in the primary-care and specialty-care fields. In this position, Mr. Molinaro is responsible for Emergency Medicine and Physicians Travel & Meeting Guide. He also oversees sales in advertising pages and customized programs as well as new product development and brand extensions. Before moving to Quadrant HealthCom, Mr. Molinaro was group publisher at Advanstar Medical Economics. Sharon J. Spector Dowden Health Media Names National Advertising Manager Dowden Health Media, Montvale, N.J., has promoted Sharon J. Spector to national advertising manager for Current Psychiatry. Ms. Spector joined Dowden Health Media in September 2001 as senior account manager. Her new responsibilities have expanded to include the launch of Current Psychiatry in Primary Care, a bimonthly publication to the highest prescribers of psychiatric medications. Medical-Education POOL Michael J. Raffin Nexus Communications Hires Senior Medical Writer Nexus Communications, a global healthcare communications and education company based in North Wales, Pa., has added Michael J. Raffin, senior medical writer, to its editorial team. Mr. Raffin is responsible for developing and implementing editorial projects, including strategic communication plans, manuscripts, abstracts, slides, and CME and CE activities. He is a contributing author to four scientific journal articles and a member of the American Medical Writers Association and the Drug Information Association. Previously, Mr. Raffin was a research assistant at Harvard Medical School and the University of Michigan. He earned a B.S. in biology from Trinity College. Jenine Serritella The Institute for Advanced Health Education Appoints Account Director Jenine Serritella, R.N., MBA, has joined the Institute for Advanced Health Education as account director. The Institute for Advanced Health Education, located in Union, N.J., is an accredited provider of continuing medical and pharmacy education. Ms. Serritella is a client liaison and responsible for creating and sustaining top client relationships, while providing support for the institute’s continuing medical-education programming. Previously, Ms. Serritella was an account supervisor at Torre Lazur McCann Healthcare Worldwide. She earned a B.S. in nursing at Seton Hall University and an executive MBA with a focus in healthcare management at Fairleigh Dickinson University. She is a member of the American College of Healthcare Executives and the American Nurses Association. Carole Sherwood AAF-MED Appoints Director Carole Sherwood has joined AAF-MED as associate CME director and director of project management. AAF-MED, Tarrytown, N.Y., is an independent accredited provider of continuing education for healthcare professionals, including physicians, nurses, and pharmacists. Ms. Sherwood has more than 15 years of experience in medical education. Before joining AAF-MED, she was director of the women’s health-education initiative at MediSpin. Ms. Sherwood holds a bachelor of arts degree in English from the University of Sydney, Australia. She is a member of the Alliance of Continuing Medical Education. Service POOL Dr. Anders Boss Mimi Quinones Dimensional HealthCare Adds to Clinical Operations Team Dimensional HealthCare has appointed Anders Boss, M.D., MFPM, as medical director and senior VP for scientific and clinical affairs. Dimensional HealthCare, based in Cedar Knolls, N.J., provides late-phase medical research to the pharmaceutical and medical-device industries. Dr. Boss oversees scientific and clinical operations. He has more than 15 years of experience in clinical R&D development at pharmaceutical companies and CROs. He received his medical degree from Copenhagen University and a diploma in pharmaceutical medicine from the University of London. Mimi Quinones also has joined Dimensional HealthCare as clinical project manager. Ms. Quinones manages the day-to-day activities of the company’s community-based research trials. Previously, she served as senior project manager for Merck. She holds a B.S. from Montclair State University and a MBA from Richmond College, The American International University in London. Martyn D. Greenacre Beijing Med-Pharm Selects New Chairman Beijing Med-Pharm, Coventry, Conn., has named Martyn D. Greenacre as chairman. Mr. Greenacre is building the company’s capacity to connect U.S. and European pharmaceutical firms interested in selling their products into the Chinese marketplace. Mr. Greenacre currently serves as a director of Acusphere, Cephalon, Curis, and Immune Response. He replaces Peter Coker, who continues to serve as a director. Erik Halstrom FFF Enterprises Appoints Business Development Leader FFF Enterprises has hired Erik Halstrom as VP of business development. FFF is a healthcare company based in Temecula, Calif. Working with LifeTree Technology, FFF’s clinical development electronic data capture company, Mr. Halstrom creates collaborative business development strategies for bringing new drugs to market. He also is engaged in postmarket surveillance of existing biopharmaceutical products. Previously, Mr. Halstrom worked in Merck’s vaccine division as director of worldwide marketing and planning for new products and director of institutional customer marketing and planning. Kay Harwood AllPoints Research Appoints Qualitative Research Consultant Kay Harwood has joined AllPoints Research as a qualitative research discovery consultant and moderator. AllPoints Research is a marketing research firm based in Winston-Salem, N.C. Ms. Harwood, who is based in Charleston, S.C., is responsible for supporting the firm’s pharmaceutical, healthcare, agribusiness, and small animal health clients. Before joining AllPoints, Ms. Harwood was with Marketing Analysts. She holds a M.A. in social and organizational psychology from the State University of New York at Buffalo and a B.S. degree with honors, magna cum laude, from Virginia Tech. She is a member of the Qualitative Research Consultants Association and the American Marketing Association. Dr. Roger J. Lias Cytovance Biologics Creates VP of Sales and Business Development Position Cytovance Biologics has named Roger J. Lias, Ph.D., to fill the newly created position of VP of sales and business development. Cytovance is a biopharmaceutical contract manufacturing company located in Princeton, N.J. Dr. Lias has joined the company from KBI BioPharma, where he was VP of business development and commercial operations. He earned his Ph.D. from Cambridge University. Joseph C. Papa Cardinal Health Appoints Chairman and CEO, Pharmaceutical Technologies and Services Joseph C. Papa has joined Cardinal Health as chairman and CEO of the company’s pharmaceutical technologies and services business. In this position, Mr. Papa is responsible for the products and services Cardinal Health offers pharmaceutical and biotech companies worldwide. Before joining the Dublin, Ohio-based company, Mr. Papa, 49, was the president and chief operating officer of Watson Pharmaceuticals. He holds a B.S. in pharmacy from the University of Connecticut and a MBA in marketing and finance from Northwestern University’s Kellogg Graduate School of Management. Mikael Reimerson invivodata Names VP, International Mikael Reimerson has joined invivodata as VP, international. invivodata, based in Pittsburgh, provides electronic patient-reported clinical-trial outcomes data. Based at invivodata’s European headquarters in London, Mr. Reimerson manages the execution of all invivodata studies conducted outside the United States. He has 25 years of experience in international operations in the pharmaceutical and telecommunication industries. Previously, he was the VP of operations at Clinitrac. Technology/Web POOL Ronald Lacy Intrasphere Technologies Appoints VP, Program Management Ronald Lacy has joined Intrasphere Technologies as VP, program management. Mr. Lacy serves Intrasphere’s mid-West customers. Intrasphere, with offices in New York and London, is a technology-consulting firm with a core focus on the life-sciences industry. Previously, Mr. Lacy, 32, was director of production, pharmaceutical services, for Solutia. He holds a MBA from Washington University’s Olin School of Business and a B.S. in computer engineering from the University of Illinois. Please send your personnel announcements to feedback@pharmavoice.com.

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK